Measuring serum prothrombin in patients treated with warfarin or direct oral anticoagulants

Clin Chim Acta. 2021 Dec:523:224-230. doi: 10.1016/j.cca.2021.09.023. Epub 2021 Sep 29.

Abstract

Background: Warfarin therapy influences generation of γ-carboxyglutamyl (Gla) residues in prothrombin, causing reduced coagulation activity. It will leave such inactive prothrombin in serum after clot formation, resulting in serum prothrombin constituting total inactive prothrombin in these patients.

Methods: An ELISA was developed to measure biologically inactive prothrombin in serum, and applied to serum from warfarin therapy causing a decrease in Gla residues or direct oral anticoagulant (DOAC) therapy as its contrast.

Results: The concentrations of serum prothrombin in both the warfarin and DOAC groups were higher than those in the healthy group (p < 0.01 and p < 0.001, respectively). When serum in the previous three groups was treated with barium carbonate to exclude prothrombin, which lost several Gla residues, the prothrombin concentration in the DOAC group decreased to the same level as that in the healthy group, indicating that prothrombin was obtained at a high level only in the warfarin group (p < 0.01).

Conclusions: Warfarin and DOAC led to increase in serum prothrombin concentration. The reason is that DOAC decreases prothrombin recruitment during fibrin clot formation, while warfarin leads to the accumulation of inactive prothrombin, which have a decreased number of Gla residues.

Keywords: DOAC; Prothrombin; Serpin; Warfarin.

MeSH terms

  • Administration, Oral
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • Blood Coagulation Tests
  • Humans
  • Prothrombin
  • Warfarin* / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Prothrombin